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PERSPECTIVES IN RENAL MEDICINE
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Posttransplant erythocytosis. Posttransplant erythrocytosis (PTE) ropoietin secretion peaks within 3 days, reticulocytosis
is defined as a persistently elevated hematocrit to a level greater begins at about 1 week, and correction of anemia is antici-
than 51% after renal transplantation. It occurs in 10% to 15% pated over 3 months. Thereafter, erythropoietin levelsof graft recipients and usually develops 8 to 24 months after
decline in a negative feedback fashion over the next 4 toengraftment. Spontaneous remission of established PTE is ob-
8 months toward normal levels [3–5]. The type of immuno-served in one fourth of the patients within 2 years from onset,
whereas in the remaining three fourths it persists for several suppression, the level of graft function, and the occurrence
years, only to remit after loss of renal function from rejection. of acute rejection appear to influence the rate of correc-
Predisposing factors include male gender, retention of native
tion of renal anemia and the level of hematocrit attainedkidneys, smoking, transplant renal artery stenosis, adequate
[1, 3]. Thus, steady-state hematocrit values vary widelyerythropoiesis prior to transplantation, and rejection-free
course with well-functioning renal graft. Just as in other forms after transplantation.
of erythrocytosis, a substantial number (60%) of patients Importantly, in a substantial subset of renal transplant
with PTE experience malaise, headache, plethora, lethargy, recipients, true polycythemia actually develops, a condi-
and dizziness. Thromboembolic events occur in 10% to 30% of
tion dubbed posttransplant erythrocytosis (PTE). Thethe cases; 1% to 2% eventually die of associated complications.
prevailing enhanced erythropoiesis is evidenced by in-Posttransplant erythrocytosis results from the combined tro-
phic effect of multiple and interrelated erythropoietic factors. creased red blood cell mass, enhanced reticulocytosis,
Among them, endogenous erythropoietin appears to play the and heightened iron utilization [6, 6a]. Although effec-
central role. Persistent erythropoietin secretion from the dis- tive therapies have been developed, the pathogenesis ofeased and chronically ischemic native kidneys does not con-
PTE remains unclear. The purpose of this perspectiveform to the normal feedback regulation, thereby establishing
is to provide an overview of the epidemiology, clinicala form of “tertiary hypererythropoietinemia.” However, eryth-
ropoietin levels in most PTE patients still remain within the manifestations, and therapeutic modalities of PTE, and
“normal range,” indicating that erythrocytosis finally ensues to critically examine the possible mechanisms involved
by the contributory action of additional growth factors on ery- in its pathogenesis.throid progenitors, such as angiotensin II, androgens, and insu-
lin-like growth factor 1 (IGF-1). Inactivation of the renin-angio-
tensin system (RAS) by an angiotensin-converting enzyme
EPIDEMIOLOGY(ACE) inhibitor, or an angiotensin II type 1 AT1 receptor
blocker represents the most effective, safe, and well-tolerated Posttransplant erythrocytosis is defined by most as a
therapeutic modality. persistently elevated hematocrit to a level greater than
51% in renal graft recipients. Its prevalence is on the
order of 10% to 15%, varying from as low as 2.5% to as
Two major factors contribute to the correction of ane- high as 22.2% [6–16]. The wide variability in the reported
mia after successful renal transplantation: adequate pro- prevalence of PTE can be explained, in part, by the follow-
duction of erythropoietin by the transplanted graft; and ing three factors. First, investigators have used different
elimination of bone marrow inhibitors attending the ure- cut off values of hematocrit (50% to 54%) to define PTE
mic syndrome [1–2]. With immediate graft function, eryth- [7–9, 17–22]. Others have actually employed gender-speci-
fic hematocrit cutoff values (53% to 55% for men, and 48%
to 51% for women) [10, 11, 23]. Second, some authorsKey words: posttransplant erythrocytosis, erythropoietin, angiotensin-
converting enzyme. included all patients who exceeded the cutoff value at
any time after transplantation, whereas others aimed toReceived for publication May 7, 2002
exclude patients with transitory erythrocytosis by requir-and in revised form June 17, 2002
Accepted for publication July 22, 2002 ing persistence of PTE for more than 6 months [12, 24].
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[6, 9, 10], and adequate erythropoiesis prior to trans-
plantation, as evidenced by no or limited use of recombi-
nant human erythropoietin while on hemodialysis. In this
regard, erythropoietin levels measured in pretransplant
sera were significantly higher in patients who developed
PTE than those who did not [15]. In addition, patients
requiring treatment with recombinant human erythro-
poietin prior to transplantation (i.e., renal dialysis pa-
tients with poor endogenous erythropoietic capacity) ap-
pear “protected” from developing PTE [6].
CLINICAL MANIFESTATIONS
Posttransplant erythrocytosis occurs in patients with
well-preserved graft function [9] and represents a true
elevation of the red blood cell mass. Platelet and leuko-
Fig. 1. Percentage of male subjects in the general renal transplant cyte counts, as well as arterial blood gases, are normal.population (A ) in the United States in 1996 [22] and in patients with
No patients have splenomegaly or pulmonary diseases.posttransplant erythrocytosis (PTE) (B ) in American studies reported
in the mid-1990s [13, 15, 16, 18, 19, 23, 36]. The pathologic elevation of hematocrit has a substan-
tial impact on blood rheology, and just as in other forms
of erythrocytosis, approximately 60% of patients with
PTE experience malaise, headache, plethora, lethargy,have varied across studies [25]. Perazella et al [23] sug-
and dizziness. Notably, 10% to 30% of patients with PTEgested that PTE is more frequent when graft recipients
develop thromboembolic events and 1% to 2% eventu-are treated with cyclosporine A than with azathioprine.
ally die of associated complications [9]. These events canBy contrast, Koziak et al [26] failed to demonstrate any
involve both veins and arteries and are manifested asdifferences in hematocrit or erythropoietin levels among
thrombosis of digital or branchial arteries, thrombophle-subgroups of their general renal transplant population
bitis, stroke, or pulmonary embolus [6, 8, 9, 23, 33].who were chronically and contemporaneously treated
The prevalence of hypertension in patients with PTEwith prednisone and azathioprine, prednisone and cyclo-
sporine A, or prednisone, azathioprine and cyclosporine was on the order of 55% prior to the introduction of
A. The basis for these discrepant results is unclear, but cyclosporine A and is about 80% in the postcyclosporine
they might reflect the complexity of the erythropoietic era [7–11, 13, 14, 24, 29, 35]; these prevalence figures are
process and the heterogenous nature of PTE. not significantly different from those in the general renal
Posttransplant erythrocytosis usually develops 8 to 24 transplant population (approximately 50% and 70% in
months after successful engraftment [10, 23, 24, 27, 28]. the pre- and postcyclosporine era, respectively) [16, 36].
Spontaneous remission of established PTE is observed
in one fourth of the patients within 2 years from onset
[6, 12, 29], whereas in the remaining three fourths of the PATHOGENETIC MECHANISMS
patients, PTE persists for up to 7 years [9, 30]. It then Although incompletely understood, the pathogenesis
might remit in association with deteriorating renal func- of PTE appears to be multifactorial. Patient-specific fac-
tion due to chronic rejection [6, 29].
tors are undoubtedly involved. Thus, PTE that has devel-
A host of factors predisposing to PTE have been iden-
oped in first-graft recipients disappears after the graft istified. Male gender is an important such factor [6]. Al-
lost to rejection, only to reappear in the same patientthough men comprised 61% of the renal graft recipients
following a second successful renal transplant [18]. More-in the United States in 1996 [31], more than 80% of PTE
over, the incidence of PTE among kidney graft recipi-patients reported in American studies in the mid-1990s
ents, in whom the recipient of the contralateral donorwere men (Fig. 1). Native kidneys appear to be of para-
kidney had developed PTE, is essentially the same withmount significance for the development of PTE. Although
that in the general transplant population [37]. Consider-PTE has appeared in sporadic cases of renal transplant
able evidence points to the participation of at least threerecipients who had undergone native kidney nephrec-
hormonal systems in the pathogenesis of PTE, namelytomy [7, 9], almost all PTE patients harbor their native
erythropoietin, the renin-angiotensin system (RAS), andkidneys [8, 10, 14, 32]. Other predisposing factors include
endogenous androgens. In addition, other erythropoiesis-smoking [9, 33], transplant renal artery stenosis [34],
rejection-free course with well-functioning renal graft stimulating factors might play a contributing role.
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spite erythrocytosis in PTE leads to a shift of the
erythropoietin/hematocrit relationship to the right out-
side the normal confidence limits (Fig. 2). Some investi-
gators have calculated the “expected” erythropoietin level
for each subject’s hematocrit value from the line repre-
senting the least squares regression for erythropoietin
versus hematocrit in nonuremic individuals and have
expressed “erythropoietin overproduction” as the ratio
of observed to “expected” erythropoietin levels. In this
regard, Lezaic et al reported that “erythropoietin over-
Fig. 2. Relationship of mean plasma erythropoietin levels and hemato- production” was ten times higher in renal transplant
crit determinations in published series on posttransplant erythrocytosis patients with PTE than in their counterparts with normal(PTE) (Table 1). The dashed lines represent the 95% confidence limits
hematocrit values [44]. In addition, erythroid progenitorsfor nonuremic individuals [1]. The erythropoietin/hematocrit relation-
ship in untreated patients with PTE (closed circles within the oval from patients with PTE have increased sensitivity to eryth-
perigram) is shifted to the right due to inappropriately sustained eryth- ropoietin in vitro compared with erythroid progenitorsropoietin secretion despite erythrocytosis (a form of “tertiary hyperery-
from transplant recipients with normal hematocrits [46].thopoietinemia”). After treatment with an angiotensin-converting en-
zyme (ACE) inhibitor or an angiotensin II AT1 receptor antagonist, With the exception of phlebotomy [24], all therapies
the erythropoietin/hematocrit relationship returns within the normal that correct PTE [native kidney nephrectomy, theophyl-limits (open circles).
line, angiotensin-converting enzyme (ACE) inhibition,
or angiotensin II type 1 receptor AT1R antagonism] are
generally accompanied by a contemporaneous (although
not always statistically significant) reduction in erythro-Erythropoietin
poietin levels (Table 1) and normalization of the erythro-Erythropoietin is the major hormonal regulator of
poietin/hematocrit relationship (Fig. 2). Further, the ap-erythropoiesis. The erythropoietin-producing cell resides
pearance of reticulocytosis and the recurrence of PTEin the kidney in a peritubular location. As shown in Figure
after discontinuation of pharmacotherapy are regularly2, a negative correlation between erythropoietin secre-
preceded, and most likely driven by, erythropoietin over-tion and the oxygen-carrying capacity of blood (hemato-
secretion [13, 42, 47].crit or hemoglobin concentration) normally exists in non-
uremic individuals. Renin-angiotensin system (RAS)
Retention of native kidneys appears to be essential
Previously, we had observed that enalapril-associatedfor development of PTE in the great majority of cases.
anemia occurred in renal transplant recipients with high-Simultaneous sampling of venous blood from the native
normal hematocrit but not in their counterparts withkidneys, the graft, and the systemic circulation of PTE
lower hematocrit values. This observation led us to sug-
patients revealed that the transplanted kidney operates
gest that “RAS might be an important determinant of
within the normal feedback relationship. In stark con- hemopoiesis, while at the same time conferring suscepti-
trast, the native kidneys oversecrete erythropoietin de- bility to enalapril-associated anemia” [48]. Indeed, a pos-
spite the prevailing erythrocytosis, a form of “tertiary itive association between RAS activation and elevated
hypererythropoietinemia” [7, 8, 29, 38]. When both na- red blood cell (RBC) mass has been revealed in patients
tive kidneys were surgically removed, a prompt reduc- with congestive heart failure [49]; chronic obstructive
tion in erythropoietin levels and correction of erythro- pulmonary disease [50, 51]; essential, malignant, or reno-
cytosis has generally been reported in PTE patients vascular hypertension [52–54]; and those undergoing
[7, 39, 40]. Cases in whom PTE results from erythropoie- chronic hemodialysis [55, 56]. In all these conditions,
tin overproduction in an ischemic graft due to severe prolonged ACE inhibition is regularly followed by statis-
transplant artery stenosis [34, 41] or in whom PTE devel- tically, although not always clinically, significant decre-
oped after bilateral native kidney nephrectomy [42] rep- ments in hematocrit values.
resent the exception to the rule. That losartan, an angiotensin II AT1 receptor antago-
Several observations suggest a causal relationship be- nist, is as effective as any ACE inhibitor in the treatment
tween erythropoietin secretion and development of PTE. of PTE indicates that interference with the action of
Contrary to expectation from the normally negative feed- angiotensin II, rather than accumulation of bradykinin,
back loop between hematocrit and erythropoietin secre- is mainly responsible for the hematocrit-lowering effect
tion, mean erythropoietin level is either equal [6] or even of ACE inhibition [32]. Further, it suggests that the an-
higher in patients with PTE compared with nonerythro- giotensin II AT1 receptor itself is involved in the patho-
cytotic renal transplant controls [43–45, 45a]. This nonsup- genesis of PTE. The exact mechanism of this effect is
not yet fully understood, but angiotensin II might bepressibility of erythropoieitn synthesis and secretion de-
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Table 1. Decrements in hematocrit (Hct) and erythropoietin (EPO) levels in patients with posttransplant erythrocytosis (PTE) after
renin-angiotensin system (RAS) inactivation
No. of Hct-pre Hct-post EPO-pre EPO-post Drug Duration of treatment
Reference/year patients % % P value U/L U/L P value mg/day weeks
Islam/1990 7 56 45 0.001 23 18.6 NS Captopril 75 NA
Conlon/1993 11 52 46 0.05 61.1 18.2 0.05 Enalapril 2.5 12
Hernandez/1995 21 58 49 0.01 15.0 13 NS Captopril NA 24
Rell/1994 17 51 43 0.01 12.2 5.4 0.05 Enalapril 20 12
Wong/1994 14 53 44 0.0001 21.3 7.4 0.02 Enalapril 2.5–5 24
Torregrosa/1994 19 56 47 0.001 13.5 9 0.05 Captopril 25 12
Danovitch/1995 15 53 46 0.001 23.8 10.1 NS Enalapril 5 8
Mulhern/1995 8 54 43 0.05 22.8 9.4 0.06 Enalapril 8.5 12
Perazella/1995 10 52 44 0.001 20 12 NS Enalapril 3.5 24
Rostaing/1995 12 51 42 0.001 17.4 8.1 NS Enalapril 14 6
Morrone/1997 20 52 48 0.05 15.4 11.2 0.05 Enalapril 10 NA
Ducloux/1998 4 52 38 0.0005 17 17 NS Losartan 100 12
Mazzali/1998 27 56 46 0.05 10.2 9.7 NS Enalapril 5 12
Julian/1998 23 53 49 0.01 15.7 9.3 0.05 Losartan 35 8
Montanaro/2000 11 54 46 0.0001 13.6 7.5 0.05 NA NA
Glicklich/2001 10 53 45 0.01 9.6 11.5 NS Lisinopril or fosinopril 9.25 6.8
Abbreviations are: NS, not significant; NA, not available.
responsible for inappropriately sustaining secretion of ents with PTE compared with their counterparts with
normal hematocrit [69]. Further, angiotensin II coulderythropoietin, directly stimulating the erythroid pro-
genitors within the bone marrow, or augmenting the enhance erythropoiesis indirectly via its stimulatory ef-
production of other erythropoietic factors. fect on the adrenal cortical cells to secrete androgens [70].
Renin shares with erythropoietin the same principal site
Endogenous androgensof production—the kidney. Renal parenchymal ischemia
appears to be a common stimulus for renin and erythro- A series of clinical observations suggest that andro-
poietin secretion, as revealed by graded constriction of gens can promote erythropoiesis. Men have higher he-
the renal arteries [57] or injection of microspheres to block matocrit values than women; male dialysis patients need
blood flow in the glomerular tufts of experimental animals less exogenous erythropoietin than their female counter-
[58]. In vivo administration of renin or angiotensin II parts to achieve the same target hematocrit [71]; and an-
caused increased erythropoietin secretion [59–62]. Angio- drogens have been successfully used to ameliorate renal
tensin-converting enzyme inhibition by captopril blocked anemia [72]. Most important, men comprise almost all
the renin- but not the angiotensin II-induced stimulation of the transplant recipients, who develop PTE (Fig. 1).
of erythropoietin secretion in rats [63], while losartan Androgens exert a dose-dependent direct stimulation
blocked the angiotensin II-induced erythropoietin secre- of erythroid progenitors that have already been differen-
tion in normal volunteers [64]. Activation of RAS during tiated by erythropoietin [73]; this effect is inhibited by
hemodialysis was accompanied by erythropoietin over- androgen antagonists [74]. Androgens can also promote
secretion that was completely blocked by captopril [55]. erythropoiesis indirectly via their stimulatory effect on
Similarly, activation of RAS by fenoterol, a  sympatho- endogenous erythropoietin or via RAS activation. Eryth-
mimetic agent, stimulated erythropoietin secretion, an ropoietin levels increased when testosterone was given
effect completely blocked by losartan [65]. Decreased to anephric sheep fetuses, apparently via hepatic over-
erythropoietin concentrations after ACE inhibition have production [75]. Similarly, nandrolone injections raised
been obtained in healthy volunteers [66] and in patients erythropoietin levels in dialysis patients and such levels
with chronic renal insufficiency [67] or congestive heart returned to baseline within 4 months from discontinua-
failure [49]. Most important, decreases in erythropoietin tion of the drug [76]. Plasma renin activity is higher in
levels, albeit not always statistically significant, have been male than female rats, probably due to androgen-driven
observed after correction of PTE with ACE inhibition or renin oversecretion [77]. Orchiectomy results in lower
angiotensin II AT1 receptor blockade (Table 1). renin and angiotensinogen mRNA levels, an effect that
Beyond enhancing erythropoietin secretion, angioten- can be reversed by testosterone replacement [77, 78].
sin II might augment erythropoiesis as a growth factor.
Other erythropoiesis-stimulating factorsThus, angiotensin II has been shown to enhance erythro-
poietin-stimulated erythroid proliferation in vitro [68]. Although erythropoietin appears to play the major
role in the development of PTE [15], evidence suggestsExpression of the angiotensin II AT1 receptor on erythroid
progenitors was increased by 44% in transplant recipi- the contribution of other nonerythropoietin-mediated
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mechanisms. First, none of the available studies has re- ing hematocrit levels, leads to severe iron deficiency in
most patients [13].ported a correlation between erythropoietin levels and
hematocrit in renal transplant recipients, including those In 1989, we reported that enalapril can cause reversible
anemia in transplant recipients with high-normal hema-with untreated PTE. Second, the effectiveness of ACE
inhibitors or angiotensin II AT1 receptor antagonists in tocrit values at baseline and suggested that this effect
“. . . could potentially be used for benefit in those renaltreating PTE is not always associated with statistically
significant changes in erythropoietin levels despite con- patients who develop erythrocytosis following renal
transplantation. . .” [48] (abstract; Canzanello VJ et al,sistent lowering of hematocrit values (Table 1). More-
over, these drugs are equally effective in PTE patients Proc Am Soc Nephrol 22:416A, 1989). Since then, rela-
tively modest doses of captopril, enalapril, lisinopril, fosi-with “high” (above the upper limit of normal) or even
“low” pretreatment erythropoietin levels [79]. Third, nopril, peridropril, and ramipril have all been shown
capable to correct PTE (Table 1). Similar to the experi-spontaneous proliferation (i.e., without erythropoietin
added to the media) of early erythroid progenitors in ence in the hypertensive population, ACE inhibition is
safe and well tolerated in patients with PTE. Dry coughperipheral blood was observed in vitro in five of nine
patients with PTE compared with none of non-PTE occurs in 5% to 13% of PTE patients on an ACE inhibi-
tor and at times requires discontinuation of the drug.transplant controls [44].
Among recently proposed nonerythropoietin-medi- Renal dysfunction not attributable to acute rejection,
postural hypotension, hyperkalemia, anemia, and erec-ated mechanisms in the pathogenesis of PTE are the oligo-
peptide N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP) tile impotence might rarely occur; these side effects are
dose-dependent and improve after dosage reduction [18,and the growth factor insulin-like growth factor 1 (IGF-1).
A natural inhibitor of the pluripotent stem cell, Ac-SDKP 21, 87]. As yet, severe adverse reactions, such as angio-
neurotic edema or anaphylactoid reactions, have notis degraded by ACE. Therefore, following ACE inhibi-
tion, this inhibitory oligopeptide can accumulate in plasma been reported. Of particular interest, the angiotensin II
AT1 receptor antagonist, losartan, was shown to be aswith the potential for diminishing erythropoiesis [80].
effective in treating PTE as any ACE inhibitor pre-Although suggesting a contributory role of the oligopep-
viously tested. This development has provided an alter-tide in the hematocrit-lowering effect of ACE inhibition,
native mode of therapy, especially for PTE patients un-this mechanism does not accord with the equal effective-
able to tolerate ACE inhibition [32, 88, 89].ness of angiotensin II AT1 receptor antagonists in cor-
Following RAS inactivation, a dose-dependent de-recting PTE.
crease in hematocrit values is observed in more thanInsulin-like growth factor 1 was shown to enhance
90% of PTE patients within the first month of treatmenterythropoietin-stimulated erythroid proliferation in vitro
[20, 28, 32, 90]. The nadir hematocrit is usually reached[81, 82]. Moreover, IGF-1 was identified as the major
within 3 months from the initiation of treatment and thecirculating factor supporting erythropoiesis in anephric
attained level remains stable during long-term observa-dialysis patients with no measurable erythropoietin levels
tions for 1 to 3 years [19, 21, 87, 91, 92]. After discontinua-[83]. Plasma IGF-1, but not erythropoietin, levels are
tion of such therapy, hematocrit values rise graduallypositively correlated with hematocrit values in uremic sub-
over the next 3 months toward pretreatment levels injects and renal transplant recipients [22, 84]. Most impor-
the majority of patients [11, 12, 87, 90, 93]. However, intant, higher plasma IGF-1 levels and/or its major binding
a substantial fraction of patients (20% to 30%), erythro-proteins were identified in patients with PTE compared
cytosis fails to recur despite withdrawal of ACE inhibi-with transplant recipients with normal hematocrit values.
tion and presence of adequate renal function [90, 93].Lowering of hematocrit via prolonged ACE inhibition
Because activation of the renal A2 adenosine receptorwas associated with decreases in IGF-1 levels and in-
can stimulate erythropoietin secretion, Bakris et al [13]creases in erythroid progenitor apoptosis [22, 85, 86].
introduced theophylline, a nonselective adenosine recep-
tor antagonist, as an alternative mode of therapy of PTE.
MANAGEMENT OF PTE Indeed, in a small prospective study with eight PTE
To prevent a secondary further increase in hematocrit patients, theophylline reduced hematocrit by more than
levels in patients with PTE, it is imperative that extracel- 10 percentage points within 2 months, an effect that was
lular volume contraction (e.g., excessive diuresis, uncon- reversible and reproducible. Theophylline was used at
trolled diabetes mellitus, diarrhea, and vomiting) be rec- nonasthma doses (8 mg/kg/day), because at higher doses it
ognized and treated. When hematocrit values exceed might stimulate cyclic adenosine monophosphate (cAMP)
55%, intermittent venesection had traditionally been uti- and lose its erythropoiesis-suppressing effect. Neverthe-
lized to maintain hematocrit values below 50% to 52% less, even at relatively small doses theophylline can cause
in an effort to reduce the risk of thromboembolic events side effects, such as headache, nervousness, and insomnia
that might adversely affect the patient’s quality of life.[35]. This strategy, although quite effective in normaliz-
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CONCLUSION
Posttransplant erythrocytosis occurs in 10% to 15%
of renal graft recipients within 1 to 2 years after trans-
plantation. As summarized in Figure 3, PTE appears to
result from the combined trophic effect of multiple and
interrelated erythropoietic factors, including erythropoi-
etin, angiotensin II, androgens, and IGF-1. Inactivation
of RAS by an ACE inhibitor or an angiotensin II AT1
receptor antagonist represents the most effective, safe,
and well-tolerated therapeutic modality.
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